Re-engineering the tumor microenvironment to overcome immune suppression

Alethia Biotherapeutics is a clinical-stage biotechnology company developing innovative approaches to overcome tumor resistance in cancer treatment. Unlike traditional immunotherapies that focus on activating the immune system, Alethia’s approach aims to enhance treatment responsiveness by inhibiting the epithelial-mesenchymal transition (EMT) and remodeling the immunosuppressive tumor microenvironment to enable deeper and more sustained therapeutic responses.

Sotevtamab’s multifaceted approach involves increasing the effectiveness of standard chemotherapies by targeting key mechanisms of chemoresistance; reestablishing antigen presentation and educating the immune system against tumor antigens resulting in a warmer tumor microenvironment.

Alethia’s platform is positioned as a first-in-class resistance-targeting approach with a combination-driven clinical strategy and the potential for broad applicability across multiple cancer indications. Designed to complement rather than replace existing therapies, sotevtamab aims to serve as a critical enabler in the next generation of cancer treatment.